文献速递慢性肾脏病水电解质与酸碱血液净化与透析

依伏卡塞与西那卡塞治疗东亚透析患者继发性甲旁亢的比较

Comparison of the Oral Calcimimetics Evocalcet and Cinacalcet in East Asian Patients on Hemodialysis with Secondary Hyperparathyroidism.
PubMed 文献 · Kidney Int Rep · 2023-08-29

这项随机双盲国际多中心研究比较了依伏卡塞与西那卡塞治疗东亚血液透析继发性甲旁亢患者52周的疗效与安全性。结果显示两组iPTH较基线分别下降34.7%与30.2%,组间差异-4.4%(95%CI -13.1%, 4.3%),在预设15%非劣效界值内;依伏卡塞组胃肠道不良事件显著更少(33.5% vs 50.5%,P=0.001),低钙血症发生率无差异。

要点

  • 依伏卡塞52周iPTH降幅非劣效于西那卡塞(组间差异-4.4%,95%CI -13.1%, 4.3%)。
  • 依伏卡塞组胃肠道不良事件显著少于西那卡塞组(33.5% vs 50.5%,P=0.001)。
  • 两组低钙血症发生率无差异,未观察到重大安全性问题。

核心结论

  • 依伏卡塞可能成为东亚血液透析继发性甲旁亢患者西那卡塞的更好替代选择。

研究设计与样本

  • 随机、双盲、患者内剂量调整、平行组、国际多中心研究,比较依伏卡塞与西那卡塞治疗52周。
  • 共203例随机至依伏卡塞组、200例至西那卡塞组;总体70.1%基线iPTH≥500 pg/ml,组间无差异。

主要发现

  • 52周时iPTH较基线平均百分比变化:依伏卡塞组-34.7% vs 西那卡塞组-30.2%,组间差异-4.4%(95%CI -13.1%, 4.3%),在预设15%非劣效界值内。
  • iPTH较基线下降≥30%的患者比例:依伏卡塞组67.3% vs 西那卡塞组58.7%,组间差异8.6%(95%CI -1.8%, 19.1%)。
  • 胃肠道不良事件发生率:依伏卡塞组33.5% vs 西那卡塞组50.5%(P=0.001),依伏卡塞组显著更低。
  • 低钙血症发生率两组无差异,未观察到重大安全性问题。

临床怎么用

  • 对于东亚血液透析继发性甲旁亢患者,依伏卡塞在iPTH降低方面非劣效于西那卡塞,且胃肠道不良事件更少。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Evocalcet is an oral calcimimetic agent with proven efficacy and safety in treating secondary hyperparathyroidism (SHPT) in Japanese patients on dialysis. METHODS: This randomized, double-blind, intrapatient dose-adjustment, parallel-group, international multicenter study compared the efficacy and safety of evocalcet versus cinacalcet for 52 weeks in East Asian hemodialysis patients with SHPT. RESULTS: In total, 203 and 200 patients were randomized to receive evocalcet or cinacalcet, respectively (overall, 70.1% had baseline intact parathyroid hormone (PTH) levels ≥500 pg/ml, with no between-group difference). Mean percentage changes in intact PTH levels from baseline were -34.7% and -30.2% in the evocalcet and cinacalcet groups at 52 weeks (between-group difference -4.4%, 95% confidence interval [CI] -13.1%, 4.3%, below the predefined 15% noninferiority margin). Overall, 67.3% and 58.7% of patients in the evocalcet and cinacalcet groups, respectively, achieved ≥30% decrease in intact PTH levels from baseline (between-group difference 8.6%; 95% CI -1.8%, 19.1%). No major safety concerns were observed. Gastrointestinal adverse events (AEs) were significantly less frequent with evocalcet compared with cinacalcet (33.5% vs. 50.5%, P = 0.001), whereas the incidence of hypocalcemia did not differ. CONCLUSION: Evocalcet might be a better alternative to cinacalcet for East Asian patients on hemodialysis with SHPT.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Ni Z, Liang X, Wu CC, et al. Comparison of the Oral Calcimimetics Evocalcet and Cinacalcet in East Asian Patients on Hemodialysis with Secondary Hyperparathyroidism. Kidney Int Rep. 2023. PMID: 38025238. doi:10.1016/j.ekir.2023.08.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。